查看文章

Alcohol use disorder (AUD) is highly prevalent, causes an immense burden of disease, and presents largely unmet clinical needs. The condition is characterized by a relapsing course of harmful alcohol consumption, excessively biased choices towards alcohol over healthy activities, and an apparent resistance to change this dysfunctional behavior, making treatment development very demanding [1]. Existing pharmacotherapies have limited efficacy and medication development is stagnant for many years now. The current ‘psychedelic renaissance’rekindled some optimism, initially inspired by promising anecdotical accounts of lasting improvements after a single or a few therapeutic sessions, and now reinforced by the emergence of governmentally funded clinical trials in some countries. These trials are focusing mostly on treatment efficacy, but rarely address any mechanism of action that are crucial for treatment …